Seres Therapeutics, Inc. beat EPS estimates 100% of the time across 2 reported quarters (2 beats, 0 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-2.07 | $-1.50 | +27.5% | Beat |
| Q12026 FY2026 | — | $-2.08 | — | Miss |
| Q42025 FY2025 | $-2.39 | $-1.89 | +20.9% | Beat |
Back to MCRB overview · MCRB holders · MCRB KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.